Plasma exchange as a cost-effective option for treating Guillain-Barré syndrome
- PMID: 28450897
- PMCID: PMC5400150
- DOI: 10.1177/1756285616659978
Plasma exchange as a cost-effective option for treating Guillain-Barré syndrome
Conflict of interest statement
Conflict of interest statement: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Buenz has been employed by Talecris (Grifols) and Terumo BCT, manufacturers of IVIG and PLEX, respectively. He has served as a Medical Advisor for Terumo BCT.
References
-
- Furlan J.C., Barth D., Barnett C., Bril V. (2016) Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Muscle Nerve 53(6): 872–876. Epub ahead of print 26 November 2015. doi: 10.1002/mus.24960. PubMed PMID: 26521889. - DOI - PubMed
-
- Jones P., Sopina E., Ashton T. (2014) Resource Implications of a national health target: the New Zealand experience of a shorter stays in emergency departments target. Emerg Med Australas 26: 579–584. - PubMed
-
- Raphael J., Chevret S., Hughes R., Annane D. (2012) Plasma exchange for Guillain–Barre syndrome. Cochrane Database Syst Rev 7: CD001798. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
